Pipeline:
Drugs for all TFs linked to disease

Despite being among the most well-known and well-researched regulatory proteins driving cancer, diabetes, and cardiovascular and neurological diseases, transcription factors (TFs) remain a major unmet clinical need. 

While more than 1,700 TFs have been identified and 200 linked to cancer, only 10 TFs have approved drugs today. 

Our first programs advancing therapeutics for cancers also reveal critical new insights to inform the future development of treatments for these other TF-driven diseases.

No Data Found

We validated each of the 4 newly
discovered TF inhibitors

Pipeline

Brachyury Program

Chordoma, a rare malignancy arising near the spine, poses therapeutic challenges due to its location and resistance to known therapeutics. The transcription factor Brachyury is the definitive driver of chordoma pathogenesis.

Beyond chordoma, brachyury is overexpressed in many other cancer types: lung, breast, prostate, liver, and brain. It is also critical in metastasis.
Talus is advancing a first-in-class small molecule inhibitor of brachyury for initial use in recurrent chordoma.

Beyond Transcription Factors

MARMOT measures more than just transcription factors. The technology also takes into account anything that interacts with DNA and chromatin: transcriptional cofactors, DNA damage response machinery, DNA replication, RNA modification, splicing, chromatin remodeling, and cellular structural proteins, and a lot of data points that are relevant for drug discovery beyond these ‘undruggable’ targets.

Beyond Transcription Factors

MARMOT measures more than just transcription factors. The technology also takes into account anything that interacts with DNA and chromatin: transcriptional cofactors, DNA damage response machinery, DNA replication, RNA modification, splicing, chromatin remodeling, and cellular structural proteins, and a lot of data points that are relevant for drug discovery beyond these ‘undruggable’ targets.